Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events

PURPOSE: Biological therapies are currently the mainstay in the treatment of patients with inflammatory bowel diseases (IBD). Several factors are known to influence the efficacy and tolerability of biologicals, such as CRP levels or previous biological use. Whether patient sex affects the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lie, Mitchell R. K. L., Paulides, Emma, van der Woude, C. Janneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340671/
https://www.ncbi.nlm.nih.gov/pubmed/32592091
http://dx.doi.org/10.1007/s00384-020-03663-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340671/
https://www.ncbi.nlm.nih.gov/pubmed/32592091
http://dx.doi.org/10.1007/s00384-020-03663-2

Ejemplares similares